ISPOR - Cost-Effectiveness Analysis of Intravitreal Aflibercept Compared with Ranibizumab-Prn in Patients with wet Age-Related Macular Degeneration (Wamd)

Full Text

Cost-Effectiveness Analysis of Intravitreal Aflibercept Compared with Ranibizumab-Prn in Patients with wet Age-Related Macular Degeneration (Wamd)

Abstract

Authors

ZA Murra Anton

Back to Volume 18, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now